Cardiac Complication, Covid19
Conditions
Keywords
Covid19, Cardiovascular Disease, Echocardiography
Brief summary
The primary objective of the study is to assess the cardiac status of COVID-19 pneumonia patients during 1 year after discharge
Detailed description
Although COVID-19 manifests in most cases with respiratory symptoms, cardiovascular abnormalities is common in hospitalized patients. Patients with cardiovascular risk factors or established disease appear to have a worse prognosis. Myocardial dysfunction could be a direct manifestation of COVID-19. The investigators hypothesize that subjects after COVID-19 pneumonia present myocardial and vascular remodeling during 1 year after discharge, even in the absence of prior cardiovascular disease.
Interventions
DIAGNOSTIC_TESTEvaluation of clinical, instrumental and laboratory diagnostics tests
During follow-up visits patients undergo clinical, instrumental and laboratory diagnostics tests
Sponsors
Tomsk National Research Medical Center of the Russian Academy of Sciences
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
-Patients with documented COVID-19 pneumonia
Exclusion criteria
* Patients with cancer * Impossible to follow up
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Echocardiographic assessment of cardiac function | up to one year | Echocardiographic assessment of global strain parameters at 3 and 12 months after discharge |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| МАССЕ | up to one year | Major adverse cardiac and cerebrovascular events: cardiac death, myocardial infarction, or stroke at 3 and 12 months after discharge |
| Quantitative analysis of parenchymal lung damage | up to one year | Describe the parenchymal lung damage through a quantitative analysis with chest CT at 3 and 12 months after discharge |
| Functional exercises capacity assessment | up to one year | Six-min walk test at 3 and 12 months after discharge |
| Evaluation of renal function | up to one year | Measure of creatinine clearance at 3 and 12 months after discharge |
| Evaluation of inflammation | up to one year | Analysis for C-reactive protein at 3 and 12 months after discharge |
| Evaluation of coagulation abnormality | up to one year | Analysis for activated clotting time at 3 and 12 months |
| Evaluation of quality of life in first year after discharge | up to one year | Assessment of the Short Form Health Survey (SF36) at 3 and 12 months after discharge |
Countries
Russia
Contacts
PRINCIPAL_INVESTIGATORElena Yaroslavskaya, PhD
Tyumen Cardiology Research Center
Outcome results
None listed